A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
NCT06549595Phase 3Recruiting
- Lead sponsor
- AstraZeneca (Industry)
- Enrollment
- 1,018 (estimated)
- Start date
- 7 Aug 2024
- Primary completion
- 26 Nov 2031 (estimated)
- Study completion
- 26 Nov 2031
- Last update posted
- 21 Oct 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- None
- Arms
- 3
Interventions
- Surovatamig Drug
- R-CHOP Drug
- R-CVP Drug
- BR Drug
Conditions and primary outcome
- Untreated Follicular Lymphoma
Primary outcome
SRI Primary: Incidence, nature and severity of AEs and SAEs. Incidence and nature of study drug discontinuations, dose reductions, and dose delays due to AEs (Up to 10 years); SRI Primary: Determination of the recommended Phase III dose (RP3D) (Up to 1 year); Phase 3 Dual Primary: To demonstrate the superiority of Surovatamig plus rituximab compared to Investigator's choice of SoC chemoimmunotherapy (Up to 10 years); Phase 3 Dual Primary: To demonstrate the superiority of Surovatamig plus rituximab compared to Investigator's choice of SoC chemoimmunotherapy (Up to 10 years)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT06549595.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT06549595 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.